Rapid and nearly complete suppression of plasma kallikrein activity with the oral inhibitor KVD900: results of a phase 1 study evaluating KVD900’s potential as a treatment for acute attacks of HAE

Maetzel A1, Smith MD1, Morten RM2, Hampton SL2, De Donatis GM2, Murugesan NI1, Rushbrooke LJ2, Li L1, Duckworth EJ2, Feener EP1, Yea CM2
KalVista Pharmaceuticals – 1: Cambridge, MA, USA 2: Porton Down, UK

**Objectives**

- Single doses of KVD900 (powder in capsule & tablet) in healthy male volunteers:
  - ...safety and tolerability
  - ...pharmacokinetics (PK)
  - ...pharmacodynamics (PD)
  - ...exposure fasted vs. fed

**Methods**

- Single oral administration of up to 600 mg KVD900 is generally safe and well tolerated
- KVD900 achieves rapid suppression of plasma kallikrein activity
- KVD900 achieves sustained protection of HK
- KVD900 concentrations rapidly exceed multiples of IC50 within 20 minutes irrespective of food intake
- Phase 2 study currently ongoing to evaluate KVD900 for on-demand suppression of attacks

**Conclusions**

- HAE attacks are unpredictable in frequency and severity
- Immediate access to on-demand treatment for HAE attacks is mandatory
- A rapid oral, on-demand treatment may stop attacks early at onset, addressing a significant worldwide need of HAE patients

**Methods - Analytics**

- Tandem MS-MS for KVD900 concentrations
- Dextran sulfate (DXS) stimulation (whole plasma):
  - fluorogenic enzyme assay (whole plasma)
  - capillary-based high molecular weight kininogen (HK) cleavage immunoassay (whole plasma)

**Results - Safety**

- No SAEs reported
- 25/26 AEs were mild
  - One moderate (headache at 10mg)
  - No GI AEs considered related to KVD900
- No subjects withdrawn
- No clinically significant changes in vital signs, ECG, safety labs

**Methods - PK:**

- Administration of single doses of KVD900 up to 600 mg is generally safe & well tolerated

**PK:**

- KVD900 rapidly achieves maximal plasma exposure
- The KVD900 tablet formulation further exceeds the fast absorption seen with the capsule

**Pharmacodynamics**

- KVD900 concentrations rapidly exceed multiples of IC50 within 20 minutes irrespective of food intake
- KVD900 maintains near complete suppression of PKa enzyme activity
- HK cleavage protection is upheld for up to 12 hrs

**Background**

- HAE attacks are unpredictable in frequency and severity
- Immediate access to on-demand treatment for HAE attacks is mandatory
- Early initiation of on-demand treatment significantly shortens attack duration
- A rapid oral, on-demand treatment may stop attacks early at onset, addressing a significant worldwide need of HAE patients

**Methods - PD:**

- Single oral administration of up to 600 mg KVD900 is generally safe and well tolerated
- KVD900 achieves rapid suppression of plasma kallikrein activity
- KVD900 achieves sustained protection of HK
- KVD900 concentrations rapidly exceed multiples of IC50 within 20 minutes irrespective of food intake
- Phase 2 study currently ongoing to evaluate KVD900 for on-demand suppression of attacks

Conflicts: All authors are or were employees of KalVista Pharmaceuticals during the execution of this work